A Phase IV Study Of The Impact Of Vorinostat On Cellular Signaling And Cytokine Production In Cutaneous T-Cell Lymphoma Patients With Pruritus
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 30 Jan 2015
Price : $35 *
At a glance
- Drugs Vorinostat (Primary)
- Indications Mycosis fungoides
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 26 Jan 2015 Planned End Date changed from 1 Mar 2016 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 26 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.